[31P]/[1H] Nuclear magnetic resonance study of mitigating effects of GYKI 52466 on kainate-induced metabolic impairment in perfused rat cerebrocortical slices

Epilepsia

Volumn 39, Issue 6, 1998, Pages 577-583

  Tang, Pei ^a   Liachenko, Serguei ^a   Melick, John A ^a   Xu, Yan ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Brain slice; Excitotoxicity; GYKI 52466; Kainic acid; Nuclear magnetic resonance; Status epilepticus

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; ADENOSINE TRIPHOSPHATE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; ASPARTIC ACID; BENZODIAZEPINE DERIVATIVE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; LACTIC ACID DERIVATIVE; MAGNESIUM; N ACETYLASPARTIC ACID; N-ACETYLASPARTATE; NEUROPROTECTIVE AGENT; PHOSPHORUS; PROTON;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; EPILEPTIC STATE; NERVE EXCITABILITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OXYGENATION; PH MEASUREMENT; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; ANIMAL; BRAIN CORTEX; CEREBROSPINAL FLUID; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH; WISTAR RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ASPARTIC ACID; BENZODIAZEPINES; CEREBRAL CORTEX; CEREBROSPINAL FLUID; ENERGY METABOLISM; EXCITATORY AMINO ACID ANTAGONISTS; HYDROGEN-ION CONCENTRATION; KAINIC ACID; LACTATES; MAGNESIUM; MAGNETIC RESONANCE SPECTROSCOPY; NEUROPROTECTIVE AGENTS; PHOSPHORUS ISOTOPES; PROTONS; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; STATUS EPILEPTICUS;

EID: 0031595380     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1998.tb01424.x     Document Type: Article

References (37)

1. DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol 1995;12:316-25.
2. Ramsay RE. Treatment of status epilepticus. Epilepsia 1993;34(suppl 1):S71-81.
3. Baram TZ, Ribak CE. Peptide-induced infant status epilepticus causes neuronal death and synaptic reorganization. Neuroreport 1995;6:277-80.
4. Chang D, Baram TZ. Status epilepticus results in reversible neuronal injury in infant rat hippocampus: novel use of a marker. Brain Res Dev Brain Res 1994;77:133-6.
5. Ferraro TN, Golden GT, Smith GG, Berrettini WH. Differential susceptibility to seizures induced by systemic kainic acid treatment in mature DBA/2J and C57BL/6J mice. Epilepsia 1995;36:301-7.
6. Mayat E, Lerner-Natoli M, Rondouin G, Lebrun F, Sassetti I, Reasens M. Kainate-induced status epilepticus leads to a delayed increase in various specific glutamate metabotropic receptor responses in the hippocampus. Brain Res 1994;645:186-200.
7. Stafstrom CE, Thompson JL, Holmes GL. Kainic acid seizures in the developing brain: status epilepticus and spontaneous recurrent seizures. Brain Res Dev Brain Res 1992;65:227-36.
8. Patneau DK, Mayer ML. Kinetic analysis of interactions between kainate and AMPA: evidence for activation of a single receptor in mouse hippocampal neurons. Neuron 1991;6:785-98.
9. Bettler B, Mulle C. Review, neurotransmitter receptors. II. AMPA and kainate receptors. Neuropharmacology 1995;34:123-39.
10. Oh S, McCaslin PP. Kainate produces concentration-dependent elevation of glutamate release but not cGMP levels in cultured neuron. Gen Pharmacol 1996;27:83-7.
11. Chittajallu R, Vignes M, Dev KK, Barnes JM, Collingridge GL, Henley JM. Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature 1996;379:78-81.
12. Donevan SD, Rogawski MA, GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 1993;10:51-9.
13. Kleinrok Z, Turski WA, Czuczwar SJ. Excitatory amino acid antagonists and the anticonvulsive activity of conventional antiepileptic drugs. Pol J Pharmacol 1995;47:247-52.
14. Wasterlain CG, Shirasaka Y. Seizures, brain damage and brain development. Brain Dev 1994;16:279-95.
15. Golden GT, Smith GG, Ferraro TN, Reyes PF. Rat strain and age differences in kainic acid induced seizures. Epilepsy Res 1995;20:151-9.
16. Golden GT, Smith GG, Ferraro TN, Reyes PF, Kulp JK, Fariello RG. Strain differences in convulsive response to the excitotoxin kainic acid. Neuroreport 1991;2:141-4.
17. Espanol MT, Xu Y, Litt L, et al. Modulation of glutamate-induced intracellular energy failure in neonatal cerebral cortical slices by kynurenic acid, dizocilpine, and NBQX. J Cereb Blood Flow Metab 1994;14:269-78.
18. Jiang C, Agulian S, Haddad GG. O2 tension in adult and neonatal brain slices under several experimental conditions. Brain Res 1991;568:159-64.
19. 1H NMR study. J Neurochem 1992;59:1820-8.
20. Xu Y, Cohen Y, Litt L, Chang LH, James TL. Tolerance of low cerebral intracellular pH in rats during hyperbaric hypercapnia. Stroke 1991;22:1303-8.
21. Corbett RJ, Laptook AR, Nunnally RL. The use of the chemical shift of the phosphomonoester P-31 magnetic resonance peak for the determination of intracellular pH in the brains of neonates. Neurology 1987;37:1771-9.
22. 31P NMR resonance peak of phosphoethanolamine. Magn Reson Med 1988;6:99-106.
23. Glantz SA. Primer of biostatistics. New York: Mcgraw-Hill, 1992.
24. Carmant L, Liu Z, Werner SJ, Mikati MA, Holmes GL. Effect of kainic acid-induced status epilepticus on inositol-triphosphate and seizure-induced brain damage in mature and immature animals. Brain Res Dev Brain Res 1995;89:67-72.
25. Albala BJ, Moshé SL, Okada R. Kainic-acid-induced seizures: a developmental study. Brain Res 1984;315:139-48.
26. Kesslak JP, Yuan D, Neeper S, Cotman CW. Vulnerability of the hippocampus to kainate excitotoxicity in the aged, mature and young adult rat. Neurosci Lett 1995;188:117-20.
27. Meldrum B, Epileptic seizures. In: Seigel GJ, Agranoff BW, Wayne AR, Molinoff PB, eds. Basic neurochemistry. New York: Raven Press, 1994:885-97.
28. Wasterlain C, Epileptic seizures. In: Siegel GJ, Agranoff BW, Wayne AR, Molinoff PB, eds. Basic neurochemistry: molecular, cellular, and medical aspects. New York: Raven Press, 1989.
29. Schurr A, Payne RS, Miller JJ, Rigor BM. Brain lactate is an obligatory aerobic energy substrate for functional recovery after hypoxia: further in vitro validation. J Neurochem 1997;69:423-6.
30. Schurr A, Payne RS, Miller JJ, Rigor BM. Brain lactate, not glucose, fuels the recovery of synaptic function from hypoxia upon reoxygenation: an in vitro study. Brain Res 1997;744:105-11.
31. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 1992;59:55-61.
32. Urenjak J, Williams SR, Gadian DG, NOble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981-9.
33. Donevan SD, Yamaguchi S, Rogawski MA. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity. J Pharmacol Exp Ther 1994;271:25-9.
34. Borowicz KK, Gasior M, Kleinrok Z, Czuczwar SJ. The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics. Eur J Pharmacol 1995;281:319-26.
35. Wasterlain CG. Recurrent seizures in the developing brain are harmful. Epilepsia 1997;38:728-34.
36. Camfield PR. Recurrent seizures in the developing brain are not harmful. Epilepsia 1997;38:735-7.
37. Sillanpää M, Jojannssen S, Blennow G, Dam M. Paediatric epilepsy: pathophysiology of experimental seizures in immature animals. London: Wrightson Biomedical Publishing, 1990.